

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3646771

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEPHEN JOHN RALPH	12/12/2013
RECEIVING PARTY DATA	
Name:	CANCURE LIMITED ACN 164 438 359
Street Address:	LEVEL 2, 17 WELCH STREET
City:	SOUTHPORT
State/Country:	AUSTRALIA
Postal Code:	4215
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	14732383
Patent Number:	7455846
Patent Number:	7964400
Patent Number:	9050352
CORRESPONDENCE DATA	
Fax Number:	(949)760-9502
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9497600404
Email:	efiling@knobbe.com
Correspondent Name:	KNOBBE, MARTENS, OLSON & BEAR, LLP
Address Line 1:	2040 MAIN STREET
Address Line 2:	14TH FLOOR
Address Line 4:	IRVINE, CALIFORNIA 92614
ATTORNEY DOCKET NUMBER:	DAVI200.001APC
NAME OF SUBMITTER:	JINHEE CHANG
SIGNATURE:	/Jinhee Chang/
DATE SIGNED:	12/07/2015
Total Attachments: 6	
source=ASSIGN_DAVI200#page1.tif	
source=ASSIGN_DAVI200#page2.tif	

source=ASSIGN_DAVI200#page3.tif

source=ASSIGN_DAVI200#page4.tif

source=ASSIGN_DAVI200#page5.tif

source=ASSIGN_DAVI200#page6.tif

**CONFIRMATORY DEED
OF ASSIGNMENT**

BETWEEN

STEPHEN JOHN RALPH

AND

CANCURE LIMITED ACN 164 438 359

SMH

REF: r:\20130680\confirmatory deed of assignment_genvax.docx
©Copyright Small Myers Hughes Lawyers

**PATENT
REEL: 037228 FRAME: 0322**

Confirmatory Deed of Assignment

THIS DEED made the 12 day of December 2013

BETWEEN: STEPHEN JOHN RALPH of 18 Barrier Reef Drive, Mermaid Waters,
Queensland 4218, Australia (Assignor)

AND: CANCURE LIMITED ACN 164 438 359 of Level 2, 17 Welch Street, Southport,
Queensland 4215, Australia (Assignee)

BACKGROUND:

- A. The Assignor is the applicant/owner in respect of the Patents and the owner of the intellectual property rights in the Invention.
- B. The Assignor has agreed to assign to the Assignee absolutely, the Assignor's right, title and interest in the Patents and the Invention.

OPERATIVE PROVISIONS:

1. ASSIGNMENT

1.1 Assignment

As and from the date of this Deed, the Assignor hereby assigns to the Assignee absolutely its full right, title and interest in and to the Patents and the Invention throughout the world, including:

- (a) by way of assignment of future rights, its full right, title and interest in any and all renewals and extensions of the Intellectual Property throughout the world;
- (b) the right to progress, or apply for and progress, any applications for Patent protection or any other registered protection of the Invention throughout the world and to benefit from this; and
- (c) the right to recover and take all such proceedings as may be necessary for the recovery of damages or an account of profits or otherwise in respect of all infringements of the Patents or any resultant patent for the Invention, whether such infringements took place before or after the date of this assignment.

2. GENERAL

2.1 Counterparts

This Deed may be executed in any number of counterparts and by facsimile or electronic mail counterparts and by different persons on separate counterparts. All such counterparts shall together constitute the one Deed.

2.2 Variation

Any amendment to this Deed must be in writing executed by the parties.

2.3 Definitions

In this Deed, the following definitions apply unless the context otherwise requires:

(a) *Genvax Therapy* means:

- (i) Immune potentiating compositions: more particularly, directed to compositions of matter comprising cells exhibiting enhanced antigen presenting functions. The compositions are generally useful in facilitating the stimulation of host immune cell responses, including selective and targeted immune cell responses. The compositions of the present invention are particularly useful in the treatment and/or prophylaxis of cancers and tumours; and
- (ii) Immunomodulating compositions and uses therefor: more particularly, directed to compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses. The compositions are particularly useful in the treatment and/or prophylaxis of a range of conditions including pathogenic infections, autoimmune diseases, transplant rejection, graft versus host disease, allergies, inflammatory disease, as well as cancers and tumours;

(b) *Invention* means the Genvax Therapy; and

(c) *Patents* means the letters patent and patent applications for the Invention described in the Schedule.

2.4 Interpretation

In this Deed, unless the context otherwise requires:

(a) a reference to:

- (i) any thing includes a part of that thing;
- (ii) a party in this Deed or in any other document or agreement includes that party's permitted successors and permitted assigns;
- (b) no rule of construction applies to the disadvantage of a party because that party was responsible for the preparation of this Deed or any part of it; and
- (c) a covenant, agreement or acknowledgment on the part of or in favour of two or more persons binds them or ensures to their benefit jointly and severally.


SCHEDULE – PATENTS

GENVAX THERAPY	
Patent No. 1 Cancer Vaccine 2002	Patent No. 2 Galectin Blocker Agent 2007
US 7455846	US 9050352
US 7964400	US 14/732383
Australia 785241	Australia 2011211337
Europe 1313839	Europe 12192129.0
Canada 2408756	Canada 2542332
Japan 4943621	Japan 5021309
France 1313839	New Zealand 600778
Germany 1313839	New Zealand 627167
United Kingdom 1313839	

EXECUTION

Executed as Deed

SIGNED SEALED AND DELIVERED)
by the said **STEPHEN JOHN RALPH**)
in the presence of:)


Stephen John Ralph

M. Cozier
Independent Witness


Matthew Cozier
Full name of Witness

11 Gilpin Cr, Upper Coomera, QLD, 4209.
Address of Witness

EXECUTED by **CANCURE**)
LIMITED ACN 164 438 359 in)
accordance with Section 127 of the)
Corporations Act (Cth) 2001)


Director/Secretary

CRAIG MILES
(Print full name of Office Holder)


Director

DAVID FREDERICK HUGHES
(Print full name of Office Holder)